ArticlePloS one2025
Prevalence and predictors of transfusion-transmitted infections among blood donor types at a teaching hospital in Ghana: Implications for haemovigilance.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Article
- Prevalence of transfusion-transmissible infections and associated sociodemographic risk factors among blood donors at a tertiary care hospital in Lahore, Pakistan.BMC infectious diseases · 2026Article
- Determinants of blood transfusion-transmitted infections in donated blood.BMC infectious diseases · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionTransfusion-transmitted infections (TTIs), notably hepatitis B virus (HBV), hepatitis C virus (HCV), human immunodeficiency virus (HIV), and syphilis, remain a major threat to blood safety in resource-limited settings. Ghana mainly uses rapid diagnostic tests (RDTs) for initial screening, which may affect the accuracy of detecting TTIs.
objectiveThis study estimated the prevalence, identified sociodemographic and donor-type predictors of TTIs and compared the diagnostic yield of RDTs versus ELISA in a teaching hospital in the Central Region of Ghana.
methodsThis retrospective study analysed 10,152 available blood donors' records screened from January 2022 to March 2024. Fixed-site donors were initially screened using RDTs (SD Biosensor Standard Q® HBsAg/HCV Ab, First Response® HIV 1-2.0, Advanced Quality™ Syphilis) followed by confirmatory ELISA testing for RDT-non-reactive samples. Mobile donors underwent ELISA (ChemWell® FUSION analyser) testing only. Multivariable logistic regression was used to identify independent TTI predictors.
resultsThe overall prevalence of TTIs (infection with at least one tested pathogen) was 16.5% (95% CI: 15.80-17.20; N = 1,675), with syphilis 8.4% (95% CI: 7.83-8.91; N = 850) being the most common. Voluntary donors had a lower TTI prevalence than replacement donors (10.6% vs 19.9%, p < 0.001). Repeat donors exhibited reduced risk of HBV (aOR: 0.254, 95% CI: 0.206-0.313, p < 0.001), HCV (aOR: 0.734, 95% CI: 0.568-0.949, p = 0.018), and syphilis (aOR: 0.486, 95% CI: 0.417-0.567, p < 0.001). However, donor type itself was not a significant predictor of TTIs after adjusting for sociodemographic variables. ELISA testing identified an additional 7.3% (95% CI: 6.67-8.01; N = 422/5,754) TTI cases among RDT non-reactive fixed-site donors (missed cases).
conclusionThe high prevalence of TTIs highlights persistent blood safety challenges. Repeat donation was independently protective, reducing risks of HBV, HCV, and syphilis. To improve blood safety, it will be essential to encourage regular voluntary donations. It will also require supplementing RDTs with ELISA where feasible, and strengthening haemovigilance systems, while accounting for the cost and logistical constraints. Although NAT is the gold standard for TTI detection, nationwide implementation in Ghana is currently not feasible.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.